Yes, salbutamol is safe and recommended for this 16-week pregnant patient with asthma.
Salbutamol (albuterol) is classified as Category A by the Australian TGA and is designated as "Compatible" for use during pregnancy, making it the preferred short-acting bronchodilator throughout all trimesters of pregnancy 1.
Why Salbutamol is the Right Choice
The 2020 ERS/TSANZ Task Force guidelines explicitly state that SABAs (short-acting beta-agonists) are unlikely to cause structural anomalies, as the observed risk in clinical studies is similar to that of the general population 1. This represents the highest quality, most recent guideline evidence available.
More importantly, the guidelines emphasize a critical clinical principle: inhaled medications have been used for many years without documentation of adverse effects on the fetus, while undertreated asthma resulting in severe exacerbation with maternal hypoxia is well described to have adverse effects on the fetus 1. The risk of uncontrolled asthma far exceeds any theoretical medication risk.
Supporting Evidence Hierarchy
From Guidelines (Highest Priority):
NAEPP 2005 guidelines confirm that albuterol is the preferred short-acting beta-agonist specifically because it has "an excellent safety profile and the greatest amount of data related to safety during pregnancy of any currently available" 2
Women's experience with these drugs is extensive, with no evidence of fetal injury from short-acting inhaled beta-agonists or contraindication during lactation 2
From FDA Drug Label:
The FDA label states: "Albuterol sulfate inhalation aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 3. While this sounds cautious, it reflects standard FDA language rather than specific safety concerns. The label notes teratogenic effects only occurred in animal studies at doses far exceeding human therapeutic doses 3.
From Clinical Research:
A prospective cohort study of 824 pregnant women found no significant relationships between major congenital malformations and first-trimester or any exposure to beta-agonists 4. Another study specifically examining inhaled albuterol in pregnant asthmatic patients between 33-39 weeks found no effects on maternal blood pressure, heart rate, or fetal circulation during the first 2 hours after dosing 5.
Important Clinical Caveats
What to Monitor:
While salbutamol is safe, be aware that systemic (not inhaled) beta-agonist administration may cause:
- Maternal and fetal tachycardia
- Maternal hyperglycemia
- Neonatal hypoglycemia (if used near delivery)
- Potential tocolytic effect during labor 1
These concerns apply primarily to systemic/IV administration, not standard inhaled therapy.
Avoid This Pitfall:
Excessive use should be avoided 1. If the patient requires frequent rescue inhaler use (>2 times per week for intermittent asthma, or daily/increasing use in persistent asthma), this signals inadequate asthma control and the need to initiate or intensify controller therapy with inhaled corticosteroids 2.
The Bottom Line
At 16 weeks gestation, this patient is well past the critical organogenesis period (weeks 3-8), though salbutamol has demonstrated safety even in first-trimester exposure. The greater danger is undertreated asthma causing maternal hypoxia, which directly threatens fetal well-being. Salbutamol should be used as needed for symptom relief, with the understanding that frequent use indicates the need for maintenance controller therapy (preferably budesonide as the preferred inhaled corticosteroid in pregnancy) 2.